HIV-infected progressors and long-term non-progressors differ in their capacity to respond to an A-class CpG oligodeoxynucleotide.
We used an A-class CpG oligodeoxynucleotide to explore innate immunity in HIV infection and observed that natural killer cells from progressors showed a markedly lower IFN-gamma production in response to the oligonuclotide as compared with long-term non-progressing subjects and healthy HIV-negative individuals. This functional defect was found in patients who showed a long immunological reduction and in those who had had a recent reduction in their CD4 cell counts.
Saez
Raquel
R
Sección de Inmunología, Hospital Donostia, San Sebastian, Spain.
Echaniz
Pilar
P
de Juan
Maria Dolores
MD
Iribarren
José Antonio
JA
Cuadrado
Emilio
E
D016022:Case-Control Studies; D018450:Disease Progression; D005500:Follow-Up Studies; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis*; D007694:Killer Cells, Natural / Q000378:metabolism*; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*
D009838:Oligodeoxyribonucleotides; D007371:Interferon-gamma